Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Nonmalignant Pain Clear all
Completed Phase 2 Interventional

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306
View directory record Official record
Conditions
Constipation
Interventions
SP-333 1 mg, SP-333 3 mg, SP-333 6 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jul 22, 2026, 3:55 AM EDT
Terminated Phase 3 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

NCT00126763
View directory record Official record
Conditions
Pain
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Phoenix, Arizona • Loma Linda, California • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional

Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain

NCT00195728
View directory record Official record
Conditions
Moderate to Severe Chronic, Non-malignant Pain
Interventions
Hydrocodone/Acetaminophen on Extended Release
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
76
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2011 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

NCT00547586
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Not applicable Interventional

Pain Program for Active Coping & Training

NCT01888146
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Interdisciplinary pain program
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

NCT00487435
View directory record Official record
Conditions
Pain, Osteoarthritis, Low Back Pain
Interventions
Tapentadol (CG5503) Extended Release (ER)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
1,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
118
States / cities
Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Not applicable Interventional

Health Outcomes From Opioid Therapy for Chronic Pain

NCT00495404
View directory record Official record
Conditions
Chronic Pain, Behavior, Addictive
Interventions
Physician Treatment Guidelines
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 22, 2026, 3:55 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

NCT00765856
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

NCT01151098
View directory record Official record
Conditions
Chronic Nonmalignant Pain
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
19
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Not applicable Interventional

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population

NCT04096391
View directory record Official record
Conditions
Chronic Nonmalignant Pain, Pain, Intractable, Pain, Chronic
Interventions
Flowonix Prometra® II Programmable Infusion System, Pain Medicine
Device · Drug
Lead sponsor
Evolve Restorative Center
Other
Eligibility
22 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

NCT00312195
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Buprenorphine transdermal patch, Placebo to match BTDS
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
21
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 22, 2026, 3:55 AM EDT
Recruiting Not applicable Interventional

Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity

NCT06183281
View directory record Official record
Conditions
Chronic Pain
Interventions
CBT, Mindfulness, and Movement
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 3:55 AM EDT
Completed No phase listed Observational

Chronic Non-Malignant Pain in Cancer Patients at a Supportive Care Clinic

NCT03043378
View directory record Official record
Conditions
Malignant Neoplasms of Independent (Primary) Multiple Sites
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

NCT00226421
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone Extended Release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
31
States / cities
Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 4 Interventional Results available

Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain

NCT03761277
View directory record Official record
Conditions
Chronic Non-malignant Pain, Chronic Pain, Pain, Back, Pain, Leg
Interventions
Medtronic SynchroMed™ II infusion system, Preservative-free morphine sulfate (PFMS)
Device · Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Anchorage, Alaska • Carlsbad, California • Napa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Placebo, Naldemedine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
49
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

NCT01186770
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Naldemedine

NCT01965652
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 22, 2026, 3:55 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

NCT00365898
View directory record Official record
Conditions
Chronic Non-Malignant Pain
Interventions
Hydromorphone Hydrochloride Extended-Release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
14
States / cities
Phoenix, Arizona • Clearwater, Florida • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 22, 2026, 3:55 AM EDT
Not listed Phase 3 Interventional

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

NCT00020605
View directory record Official record
Conditions
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naloxone hydrochloride
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jul 22, 2026, 3:55 AM EDT